Polycystic ovary syndrome (PCOS) is being given a new name: polyendocrine metabolic ovary syndrome (PMOS). The reason for this change is the growing recognition that the previous name does not adequately describe the condition.
PMOS is one of the most common hormonal disorders among women of childbearing age—it affects about one in eight women worldwide. At the same time, it often takes a long time to receive a diagnosis, since symptoms are not always clearly identifiable or vary in severity.
More Than Just “Ovarian Cysts”
A key reason for the renaming lies in the term itself. “Polycystic ovaries” suggests that cysts are central to the condition. In fact, however, these are actually many small ovarian follicles and not pathological cysts.
More importantly, however, the disease affects more than just the ovaries. It is now clear that this is a complex systemic hormonal and metabolic disorder that can affect the entire body. Typical symptoms range from menstrual irregularities and skin changes to fertility problems, insulin resistance, an increased risk of diabetes, and cardiovascular disease. Psychological stress also plays an important role for many of those affected.
A name that better describes the condition
The new term PMOS reflects this understanding: “polyendocrine” indicates the involvement of multiple hormonal systems, “metabolic” emphasizes the importance of metabolism, and “ovarian” highlights the role of the ovaries. The term “syndrome” makes it clear that the course of the disease can vary greatly.
With this renaming, the international scientific community has a clear goal: to ensure that the disease is detected earlier, better understood, and treated more comprehensively. A more precise name can help identify symptoms more quickly and take long-term health effects into greater consideration.
For patients, this means, above all, greater clarity: PMOS is more than just a fertility issue—it is a medical condition that affects hormone balance and metabolism and can have long-term effects on health.